CatalystMarker
← board

PRGO

distress 0/10 · well-funded / low risk
$10.12-3%today-64% from 52w high
perrigo.com8,100 employeesFounded 1887Dublin, IrelandDrug Manufacturers - Specialty & Generic
Revenue
$969M
Liquidity
$357M
Runway
Shares 1y
+1%

Price & events

-29.6% over 6M
$9.02$11.70$14.38Jan 26Apr 26Jul 2622.4Mfinancing: 8-K material_agreement (2026-03-23)rating: Canaccord Genuity: Buy (2026-02-27)
CatalystRating changeDilutionFinancingdashed = today
-3.4%
1D
-9.4%
1W
+6.6%
1M
-11.2%
3M
-27.9%
6M
-61.8%
1Y
-59.9%
2Y
-73.5%
5Y
-72.2%
All

Overview

Market Cap
$1.40B
Enterprise Value
$4.66B
Volume
86.79K
52 Week Range
$9.25 – $28.43
Total Shares
138.37M
Float Shares
137.64M
Short %
27.28%
% Held by Insiders
0.40%
% Held by Institutions
116.73%
RVOL
0.02x
Beta
0.52

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 3

Approved drugs (1)

  • LORATADINELORATADINE2004 · Discontinued

Capital structure — dilution & financing

Shares out: 138,367,770 · 0 offerings/1y · 0 PIPEs
  • 2026-03-238-Kmaterial_agreement
  • 2025-07-148-Kmaterial_agreement
  • 2024-10-31SC 13Gstrategic_stake
  • 2024-09-178-Kmaterial_agreement
  • 2024-09-13424B5offering
  • 2024-09-12FWPoffering
  • 2024-09-09S-3ASRshelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • 2026-02-27Canaccord GenuityBuy
  • 2025-12-15JP MorganNeutral
  • 2025-11-06Canaccord GenuityBuy
  • 2025-11-06JP MorganOverweight → Neutral
  • 2025-10-27JefferiesHold
  • 2025-08-07Canaccord GenuityBuy

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.